Saturday 17 October 2026
Export ADIL’s income statement to Excel — free account
Adial Pharmaceuticals, Inc.
ADIL Healthcare Biotechnology
In the quarter to June 2026, EPS fell 150.0% and free cash flow fell 263.7%, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.49
0.35
+11.15%
Follow ADIL
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(155.00%) | (170.72%) | (265.95%) | 352.60% | |
| (130.15%) | (136.15%) | (179.08%) | (322.10%) | ||
ROIC |
0.00% | 0.00% | 0.00% | 0.00% | |
Return on Tangible Assets |
(208.64%) | (166.75%) | (235.99%) | (243.64%) | |
Average Days of Receivables |
— | — | — | — | |
Free Cash Flow per Share |
(7.47) | (9.54) | (4.76) | (2.41) | |
Free Cash Flow |
(6.62) | (6.38) | (6.52) | (11.13) | |
Capital Expenditures |
— | 0.12 | — | — | |
| Other line items | |||||
Cash ROIC |
(72.68%) | (57.15%) | (78.54%) | 115.18% | |
Accounts Payable Turnover |
0.00 | 0.00 | 0.00 | 0.00 | |
Average Days of Payables |
0.00 | 0.00 | 0.00 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | (0.93) | |
Research and Development Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Selling, General and Administrative Expense of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Share Based Compensation of Revenue |
0.00% | 0.00% | 0.00% | 0.00% | |
Operating CF/Net income |
0.82 | 0.81 | 0.84 | 0.19 | |
Depreciation/Fixed assets |
0.00 | 0.00 | 0.00 | — | |
Capex/Depreciation |
0.00 | 129.22 | 0.00 | — | |
Revenue per Share |
0.00 | 0.00 | 0.00 | 0.00 | |
Operating CF per Share |
(7.47) | (9.71) | (4.76) | (2.41) | |
Capex per Share |
0.00 | 0.17 | 0.00 | 0.00 | |
Capex to Sales |
— | 0.00 | — | — |
Columns are period end dates